CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 9 enrolled
Drug / intervention
Strattera +2 moredrug
Likely dose
Strattera 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01340885
NCT01340885Phase 4Completed
CompareCT.gov

Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study

Oregon Health and Science University·interventional·Posted Apr 25, 2011·Updated Jul 7, 2020

In Brief

A Phase 4 clinical trial evaluating Strattera, Exelon, and 1 other intervention for Parkinson's Disease. Completed, enrolled 9 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS)

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 25, 2011
Enrollment StartJan 1, 2011
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 15.2 years ago

Interventions

Stratteradrug

10-30 mg b.i.d. for 6 weeks

Exelondrug

1.5-4.5 mg b.i.d. for 6 weeks

Placeboother

2-6 pills for 6 weeks